Back to results
US 6,635,258 B2Granted
Herpes simplex virus VP22 vaccines and methods of use
AssigneeChiron Corporation
InventorsRae Lyn Burke, Michael A. Tigges
Life of this patent
Estimating the term…
Abstract
Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.
Claims24
A composition comprising an isolated polypeptide, and a pharmaceutically acceptable excipient, wherein said polypeptide shares at least one antigenic determinant with the HSV VP22 polypeptide of SEQ ID NO:
- 2, and has at least 90% sequence identity with the sequence of SEQ ID NO:
- 2.
A method of producing a composition, the method comprising:
- (a) providing an isolated polypeptide, wherein said polypeptide shares at least one antigenic determinant with the HSV VP22 polypeptide of SEQ ID NO:
- 2, and has at least 90% sequence identity with the sequence of SEQ ID NO:
- 2;
- and
- (b) formulating the polypeptide with a pharmaceutically acceptable excipient.
2 more elements
Dependencies are inferred from the claim text.